Clinical trials: Neoplasm Recurrence
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of…
- Trial name
- COBRA (NCT05249127)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Relapsed or Refractory Multiple Myeloma
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT02099539
- Testing
- N-803
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Altor BioScience
HPV-Related Cervical Carcinoma, HPV-Related Malignancy
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
This is a multi-center study in patients with recurrent or metastatic HPV16-positive, PD-L1 positive cervical cancer who has progressed during or after treatment with the first-line standard of care (pembrolizumab with…
- Conditions
- HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer
- Trial name
- NCT06099418
- Testing
- VB10.16, Atezolizumab Injection [Tecentriq]
- Sponsor
- Nykode Therapeutics ASA
Advanced Malignant Neoplasm, Locally Advanced Malignant Neoplasm
Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits
This trial assesses patient perception of physician's compassion, communication skills, and professionalism during clinic visits through the use of videos and questionnaires.
- Conditions
- Advanced Malignant Neoplasm, Locally Advanced Malignant Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm
- Trial name
- NCT03856060
- Testing
- Questionnaire Administration, Video
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Recurrent
Partial Breast Re-irradiation in Women in Women with Locally Recurrent Breast Cancer Previously Treated with Conservative Surgery and Whole Breast Irradiation
A prospective study of partial breast re-irradiation in patients with local recurrence of breast cancer
- Trial name
- PBReI (NCT05772390)
- Testing
- Partial breast re-irradiation
- Where
- Italy
- Volunteers
- 68 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Multiple Myeloma, NonHodgkin Lymphoma
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.
- Trial name
- NCT02978235
- Testing
- TAS4464
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Taiho Oncology, Inc.
Brain Tumor, Recurrent, Adult
18F-Fluciclovine PET and Multiparametric MR Imaging
The purpose of the study is to investigate the use of the investigational agent Axumin (fluciclovine-F18) with PET/CT imaging in combination with standard MR imaging to detect remaining or recurrent brain tumor.
- Trial name
- NCT03925675
- Testing
- PET/CT with F-Fluciclovine (Axumin)
- Where
- United States
- Sponsor
- Loma Linda University
Refractory Cancer, Recurrent Cancer
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A*02 eligible patients with…
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- Trial name
- NCT06372574
- Testing
- RO7617991, Tocilizumab
- Sponsor
- Genentech, Inc.
Hematologic Malignancies
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies.
- Trial name
- NCT03557619
- Testing
- Venetoclax, ethinyl estradiol/levonorgestrel
- Where
- 4 sites in United States, Australia
- Volunteers
- 12 people
- Sponsor
- AbbVie
Epithelial Ovarian Cancer, Rectosigmoid Cancer Metastatic
Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery
Ovarian cancer is the most common cause of death in gynecological cancer. Approximately 75% of epithelial ovarian cancers are detected at an advanced stage.
- Trial name
- NCT04665635
- Testing
- Rectosigmoid resection
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Cukurova University
Brain Metastases, Adult
Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
During gamma scalpel treatment of brain tumors and metastases, a follow-up magnetic resonance imaging (MRI) scan is performed. The radiologist who reviews the MRI assesses whether there is an increase in signal at the tumor site.
- Trial name
- ITIRR (NCT05095766)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Penile Cancer, Recurrent
Prediction of Local Recurrence and Its Impact on Long-term Outcomes After Low-risk Glans-sparing Surgery for Penile Squamous Cell Carcinoma
The treatment paradigm for primary penile squamous cell carcinoma (PSCC) has increasingly favored maximal organ preservation without compromising oncological outcomes.
- Trial name
- NCT06565585
- Testing
- Glans-sparing surgery
- Where
- Belgium
- Volunteers
- 800 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Fear of Cancer Recurrence
CIFeR - A Clinician-led Intervention to Address Fear of Cancer Recurrence
The investigators will test a novel Clinician-led Intervention to address Fear of cancer Recurrence in cancer survivors (CIFeR), by 1) adapting the original Australian intervention manual to the Danish oncology context…
- Trial name
- NCT06554899
- Testing
- Clinician-led intervention to address fear of cancer recurrence (CIFeR)
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
Urothelial Carcinoma
The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma
The clinical trial was designed to determine the efficacy (sensitivity and specificity) of the IUrisure test compared to the gold standard cystoscopy and pathology in patients under monitoring for recurrence of urothelial…
- Trial name
- NCT06564363
- Testing
- IUrisure test
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Advanced Cancer, Relapsed Cancer
Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents
This study will evaluate the effects of human-animal interaction on reducing anxiety, depression, worry, and pain and enhancing quality of life in children ages 6-17 years old with a life threatening cancer and their parent…
- Conditions
- Advanced Cancer, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT04310345
- Testing
- Animal-Assisted Interactions
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Recurrence Tumor, Metastatic Cancer
Immunotherapy for the Treatment of Advanced Solid Tumor
The purpose of this study is to evaluate the safety, side effects and benefits of autologous tumor infiltrating lymphocytes (TIL) specific to personalized Neo-antigens in the treatment of patients with recurrent, metastatic and…
- Conditions
- Recurrence Tumor, Metastatic Cancer, Solid Tumor
- Trial name
- NCT03658785
- Testing
- TIL, Aldesleukin, Cyclophosphamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tongji Hospital
Relapsed or Refractory Multiple Myeloma
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and…
- Trial name
- ARROW2 (NCT03859427)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 108 sites in United States, Austria and 15 more
- Volunteers
- 454 people
- Sponsor
- Amgen
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Ovarian Neoplasms
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific…
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer
- Trial name
- NCT05001282
- Testing
- ELU001
- Where
- 18 sites in United States
- Volunteers
- 79 people
- Sponsor
- Elucida Oncology
Cancer Head Neck
Single and Combined Modality Trans-Oral Robotic Surgery in Early Oropharyngeal Cancer
Multi-centre retrospective observational cohort study with optional exploratory radiomic study (international) and prospective molecular analysis studies (UK only).
- Trial name
- SCORE (NCT05933889)
- Testing
- Molecular Analysis, Radiomic/ Morphological analysis
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Royal Marsden NHS Foundation Trust